Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ranibizumab - Novartis Ophthalmics

Drug Profile

Ranibizumab - Novartis Ophthalmics

Alternative Names: AMD Fab; Anti-VEGF fragment; Lucentis; Rabinismab; RG-3645; rhuFab V2; rhuFab V2 AMD; VEGF antibody fragment

Latest Information Update: 10 Oct 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Genentech
  • Developer Genentech; Manhattan Eye, Ear & Throat Hospital; Novartis Ophthalmics; University of Bonn
  • Class Eye disorder therapies; Monoclonal antibodies
  • Mechanism of Action Angiogenesis inhibitors; Vascular endothelial growth factor A inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Choroidal neovascularisation; Degenerative myopia; Diabetic macular oedema; Retinal oedema; Wet age-related macular degeneration
  • Registered Diabetic retinopathy
  • Preregistration Retinopathy of prematurity
  • Phase I/II Polypoidal choroidal vasculopathy
  • Discontinued Retinal telangiectasis

Most Recent Events

  • 30 Sep 2019 Genentech initiates the phase III trial for Diabetic macular edema in USA (NCT04108156)
  • 19 Sep 2019 The Committee for Medicinal Products for Human Use (CHMP) adopts a positive opinion for an extension to the existing indication of ranibizumab
  • 26 Jul 2019 The CHMP of the EMEA gives a positive opinion for ranibizumab in the treatment of preterm infants with retinopathy of prematurity in the EU
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top